BUZZ-首款 PWS 饥饿疗法获 FDA 批准后，TD Cowen 以 "买入 "开始覆盖 Soleno Therapeutics

路透中文

Jun 23, 2025

BUZZ-首款 PWS 饥饿疗法获 FDA 批准后，TD Cowen 以 "买入 "开始覆盖 <a href="https://laohu8.com/S/SLNO">Soleno Therapeutics</a>

6月23日 - ** 券商TD Cowen开始对制药商Soleno Therapeutics SLNO.O进行评级，给予 "买入 "评级，并将PT值定为110美元。

** 与该股上次收盘价相比，PT上涨37.3

*) * 券商认为，SLNO的Vykat XR是首个获准治疗普拉德-威利综合征（Prader-Willi Syndrome）$(PWS)$，一种罕见遗传病的过度饥饿(食欲亢进症的药物，具有上升空间。

** "Vykat XR 的标签是最好的情况，适应症广泛，适用于 4 岁及以上的食欲过盛患者。此外，该药也没有方框警告和糖尿病禁忌症"--TD Cowen

** TD Cowen 分析师预计，到 2035 年，该公司的销售额将达到 26 亿美元的峰值。

** TD Cowen称，自3月份Vykat XR上市以来，SLNO已从131名医生处获得了268份处方，目标是在全国范围内向约1万名潜在的小儿普拉德-威利综合征患者提供专家处方。

** 截至上次收盘，SLNO 股价年累计上涨 77.9

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2545412619"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545412619\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2545412619?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-06-23 21:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545412619","market":"us","top_or_hot":-1,"title":"BUZZ-首款 PWS 饥饿疗法获 FDA 批准后，TD Cowen 以 \"买入 \"开始覆盖 Soleno Therapeutics","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-首款 PWS 饥饿疗法获 FDA 批准后，TD Cowen 以 \"买入 \"开始覆盖 <a href=\"https://laohu8.com/S/SLNO\">Soleno Therapeutics</a></title></head><body><p><span>6月23日</span><span> - </span>** 券商TD Cowen开始对制药商Soleno <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>SLNO.O</span>进行评级，给予 \"买入 \"评级，并将PT值定为110美元。</p><p> ** 与该股上次收盘价相比，PT上涨37.3</p><p> *) * 券商认为，SLNO的Vykat XR是首个获准治疗普拉德-威利综合征（Prader-Willi Syndrome）<a href=\"https://laohu8.com/S/PWS\">$(PWS)$</a>，一种罕见遗传病的过度饥饿(食欲亢进症的药物，具有上升空间。</p><p> ** \"Vykat XR 的标签是最好的情况，适应症广泛，适用于 4 岁及以上的食欲过盛患者。此外，该药也没有方框警告和糖尿病禁忌症\"--TD Cowen </p><p> ** TD Cowen 分析师预计，到 2035 年，该公司的销售额将达到 26 亿美元的峰值。</p><p> ** TD Cowen称，自3月份Vykat XR上市以来，SLNO已从131名医生处获得了268份处方，目标是在全国范围内向约1万名潜在的小儿普拉德-威利综合征患者提供专家处方。</p><p> ** 截至上次收盘，SLNO 股价年累计上涨 77.9 </p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-首款 PWS 饥饿疗法获 FDA 批准后，TD Cowen 以 \"买入 \"开始覆盖 Soleno Therapeutics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-首款 PWS 饥饿疗法获 FDA 批准后，TD Cowen 以 \"买入 \"开始覆盖 Soleno Therapeutics\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2025-06-23 21:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-首款 PWS 饥饿疗法获 FDA 批准后，TD Cowen 以 \"买入 \"开始覆盖 <a href=\"https://laohu8.com/S/SLNO\">Soleno Therapeutics</a></title></head><body><p><span>6月23日</span><span> - </span>** 券商TD Cowen开始对制药商Soleno <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>SLNO.O</span>进行评级，给予 \"买入 \"评级，并将PT值定为110美元。</p><p> ** 与该股上次收盘价相比，PT上涨37.3</p><p> *) * 券商认为，SLNO的Vykat XR是首个获准治疗普拉德-威利综合征（Prader-Willi Syndrome）<a href=\"https://laohu8.com/S/PWS\">$(PWS)$</a>，一种罕见遗传病的过度饥饿(食欲亢进症的药物，具有上升空间。</p><p> ** \"Vykat XR 的标签是最好的情况，适应症广泛，适用于 4 岁及以上的食欲过盛患者。此外，该药也没有方框警告和糖尿病禁忌症\"--TD Cowen </p><p> ** TD Cowen 分析师预计，到 2035 年，该公司的销售额将达到 26 亿美元的峰值。</p><p> ** TD Cowen称，自3月份Vykat XR上市以来，SLNO已从131名医生处获得了268份处方，目标是在全国范围内向约1万名潜在的小儿普拉德-威利综合征患者提供专家处方。</p><p> ** 截至上次收盘，SLNO 股价年累计上涨 77.9 </p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SLNO","symbol_name":"Soleno Therapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nL4S3SQ0XM:1","article_id":"2545412619","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545412619","pubTimestamp":1750684421,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-首款 PWS 饥饿疗法获 FDA 批准后，TD Cowen 以 \"买入 \"开始覆盖 Soleno Therapeutics6月23日 - ** 券商TD Cowen开始对制药商Soleno Therapeutics SLNO.O进行评级，给予 \"买入 \"评级，并将PT值定为110美元。此外，该药也没有方框警告和糖尿病禁忌症\"--TD Cowen  ** TD Cowen 分析师预计，到 2035 年，该公司的销售额将达到 26 亿美元的峰值。** TD Cowen称，自3月份Vykat XR上市以来，SLNO已从131名医生处获得了268份处方，目标是在全国范围内向约1万名潜在的小儿普拉德-威利综合征患者提供专家处方。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"SLNO":"Soleno Therapeutics","BK4139":"生物科技"},"translate_title":"BUZZ-TD Cowen starts covering Soleno Therapeutics with a \"buy\" after the first PWS starvation therapy is approved by the FDA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLNO":0.9},"content_text":"BUZZ-首款 PWS 饥饿疗法获 FDA 批准后，TD Cowen 以 \"买入 \"开始覆盖 Soleno Therapeutics6月23日 - ** 券商TD Cowen开始对制药商Soleno Therapeutics SLNO.O进行评级，给予 \"买入 \"评级，并将PT值定为110美元。 ** 与该股上次收盘价相比，PT上涨37.3 *) * 券商认为，SLNO的Vykat XR是首个获准治疗普拉德-威利综合征（Prader-Willi Syndrome）$(PWS)$，一种罕见遗传病的过度饥饿(食欲亢进症的药物，具有上升空间。 ** \"Vykat XR 的标签是最好的情况，适应症广泛，适用于 4 岁及以上的食欲过盛患者。此外，该药也没有方框警告和糖尿病禁忌症\"--TD Cowen  ** TD Cowen 分析师预计，到 2035 年，该公司的销售额将达到 26 亿美元的峰值。 ** TD Cowen称，自3月份Vykat XR上市以来，SLNO已从131名医生处获得了268份处方，目标是在全国范围内向约1万名潜在的小儿普拉德-威利综合征患者提供专家处方。 ** 截至上次收盘，SLNO 股价年累计上涨 77.9 (为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}